Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
Open Access
- 1 July 1993
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 342 (8863) , 69-73
- https://doi.org/10.1016/0140-6736(93)91283-r
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160Vaccine, 1992
- Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical TrialThe Journal of Infectious Diseases, 1992
- Slowing the spread of human immunodeficiency virus in developing countriesThe Lancet, 1991
- The spread of HIV-1 in Africa: sexual contact patterns and the predicted demographic impact of AIDSNature, 1991
- Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoproteinThe Lancet, 1991
- The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in HumansAnnals of Internal Medicine, 1991
- Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160Nature, 1990
- Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccinationVaccine, 1989
- AGE-RELATED RESPONSE TO HEPATITIS B VACCINE IN THE MENTALLY RETARDEDThe Lancet, 1984
- Hepatitis-B Vaccination in the ElderlyThe Journal of Infectious Diseases, 1984